Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant for Intracranial Pressure in Traumatic Brain Injury
NCT03035838Phase 1Withdrawn
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of fosaprepitant in traumatic brain injury (TBI). Primary endpoint: Reduction in intracranial pressure up to 5 days. Planned start Nov 2021; status: withdrawn.
02
Drugs
fosaprepitant
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT03035838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03035838.